Articles tagged with Lung Tumors
Researchers from CNIO achieved complete remission in 25% of lung tumors induced by KRAS oncogene in mice following genetic inactivation of CDK4 and RAF1. This strategy also prevented cancer cell growth in healthy mice and identified molecular mechanisms that triggered resistance, such as PI3K pathway activation.
Scientists discovered that identifying tumor-associated macrophage patterns in lung tumor tissue enables the prediction of disease progression. The study found that a higher number of tumor-promoting macrophages near the invasive margin is associated with lower patient survival rates.
Researchers at Lund University developed a novel surgical technique combining with smart nanoparticles to target lung tumors. The approach has shown promise in animal models, allowing for selective tumor targeting and reduced side effects.
PRRT is an approved treatment modality for gastroenteropancreatic neuroendocrine tumours, particularly in midgut NETs. In Australia, PRRT is used more widely than previously thought, despite limited Phase III trial data for lung NETs.
The BIO Integration Journal bridges the gap between laboratory, clinic, and biotechnology industries, offering a cross-disciplinary platform for biomedical research advances. Featured papers emphasize interdisciplinary integration in COVID-19 research and immunotherapy strategies.
A study suggests that blocking two sugar-transporting proteins could help slow the growth of lung tumors. Researchers genetically engineered mice with lung cancer and found that tumors grew slower when both glucose transporters were lacking.
Scientists have made a breakthrough discovery in understanding small cell lung cancer, finding that it can change and adapt to evade treatments. The study suggests that the tumor is like a 'moving target' that requires multiple treatments to be effective.
Researchers developed a new approach to detecting lung cancer using nanoparticles that can interact with enzymes linked to the disease. The sensors were tested in mice and found to accurately detect tumors at an early stage, reducing false positives.
Researchers at Mount Sinai have found a way to regulate special immune system cells in lung cancer tumors, suppressing them and allowing tumors to grow. By blocking this pathway, the immune system can be boosted to prevent tumor formation or growth, offering a potential new treatment for immunotherapy.
A new tumor-highlighting technology called OTL38 enhances the visualization of lung cancer tissue, improving patient outcomes. Researchers found that OTL38 helped identify 10 additional cancers in 7 patients and improved margins for 26% of patients.
Researchers have discovered that inhibiting p38 reduces the growth of lung tumors in genetic mouse models. Lower levels of p38 in tumors are associated with a more favorable prognosis for patients.
Research reveals frequent RB1 intragenic rearrangements in non-smoking patients with EGFR mutations, indicating higher resistance to EGFR inhibitors. The alteration may favor growth and tumoural versatility of resistant clones.
Researchers have found that anti-cancer agents with low-molecular weights cannot reach tumors effectively due to obstructed small arteries. This limits the use of conventional chemotherapy and highlights the need for new treatments, according to Professor Tetsuya Kodama.
Researchers developed nanoparticles that can deliver immunostimulants via inhalation to induce systemic immune response against lung cancer. The treatment converted cold tumors to hot, immune-responsive tumors and showed significant regression of tumors in both lungs and prolonged survival of mice.
Researchers at UCLA Jonsson Comprehensive Cancer Center identified a new biomarker tracking mitochondrial activity in lung tumors using noninvasive imaging. This level of activity may predict favorable response to complex I inhibitor and inform treatment decisions for individuals with lung cancer.
Researchers have discovered that patients' blood samples and tumour biopsies can reveal early signs of lung cancer spreading and becoming untreatable. The TRACERx project has identified possible causes of recurrence and developed new techniques to predict tumour aggression.
Scientists have identified a molecular mechanism that causes lung cells to lose their identity, promoting tumor growth. The study reveals how genetic mutations coordinate pathways to drive malignancy in lung cancer, shedding light on mechanisms of tumor progression and influencing drug development.
Researchers discovered that a deficiency of TSC2 produces dysfunctional molecules leading to PAH. The protein's role in maintaining healthy pulmonary blood vessels has significant therapeutic implications.
Researchers have developed a mini-protein MYC inhibitor that effectively treats non-small cell lung cancer, exhibiting minimal side effects. The therapy works by targeting the MYC oncogene, leading to reduced tumor growth and improved patient outcomes.
Researchers used Raman spectroscopy to map biomolecular changes in radiation-resistant and radiation-sensitive human lung tumors and head and neck tumors. They found statistically significant differences in lipid and collagen content that could potentially identify treatment-resistant tumors early.
A new study uses Raman spectroscopy to analyze changes in biochemical composition of tumors, enabling prediction of radiation response. The findings have the potential to reduce medical overtreatment and improve treatment plans for cancer patients.
A new assay can identify patients with lung cancer and quantify PD-L1 expression levels using small, unfixed tissue samples collected via minimally invasive bronchoscopy. This approach can guide therapeutic decisions and potentially save time and money.
Researchers found that lung tumors exploit altered bacterial populations to create an inflammatory environment that promotes their survival. Treating mice with antibiotics or blocking immune cells significantly reduced tumor size.
Researchers have identified 52 distinct cell types in lung tumors, far more than previously thought, offering new avenues for treatment and research. The study's findings will help develop strategies to fight tumor growth and test new immunotherapy targets.
IDMC recommends continuing Zepsyre® (lurbinectedin, PM1183) Phase III trial in small-cell lung cancer patients. The pivotal trial assesses the efficacy of PM1183 in combination with doxorubicin compared to standard treatments.
Researchers found that a type of lung cancer's spread is facilitated by immune cells forming clots in tumors. These clots allow tumor cells to migrate and spread to other parts of the body. The study identifies a new target for potential metastasis treatment.
A new study published in Journal of Clinical Oncology shows a four-year overall survival rate of 96 percent for patients with stage IV Wilms tumors with lung metastases, compared to 84 percent on the predecessor study. The approach resulted in sparing initial upfront lung radiation and reducing long-term risks for nearly half of patients.
A new study discovered an antibody that can prevent tumors from shedding proteins the immune system uses to identify and attack them. In mouse models of melanoma and lung cancer, this antibody increased natural killer cell infiltration into tumors, reducing their load.
A team of researchers found that lung tumor cells can revert to a developmental program similar to their nearest relatives when a key gene is lost. This discovery highlights the remarkable resilience and adaptability of cancer cells.
Researchers develop a genetic model that eliminates c-Raf kinase, causing tumor regression with low toxicity; validation opens new possibilities for therapies against KRAS-driven cancers. Lung cancer remains a leading cause of cancer-related deaths worldwide.
International organizations IASLC and BTOG are partnering to spread awareness of revised lung cancer staging criteria. The new system takes effect this month and aims to provide better care for patients. Key findings highlight improved prognostic factors, tumor size measurements, and coding systems for lung cancers with multiple lesions.
Studies using mouse models of lung cancer found that neutrophils help tumors hide from T cells and promote their own growth through the production of Snail protein. This 'vicious cycle' between neutrophils and tumor cells hinders immunotherapy's effectiveness in up to two-thirds of patients.
Researchers have identified a communication network between lung tumors and bone marrow that contributes to tumor progression. Tumors activate osteoblasts in the bone marrow, leading to the production of immune cells that promote cancer growth.
Researchers found that cell-free tumor DNA circulating in the bloodstream correlates with tumor metabolism rather than tumor burden in advanced non-small cell lung cancer patients. This study suggests that circulating tumor DNA may be a reliable biomarker to identify potential unresponsive NSCLC patients before treatment.
A new blood test can predict how early-stage lung cancer patients will fare, identifying clusters of aggressive tumor cells that indicate shorter survival times. The test uses circulating tumor cells in the bloodstream to monitor cancer progression and resistance to treatments.
Researchers found that patients with deeper tumor shrinkage due to targeted treatment had better progression-free survival and overall survival rates. The study suggests that initial response could be an early indicator of a drug's effectiveness, influencing both clinical trials and treatment goals.
Researchers found that a kinase-inactive Braf mutant triggers lung adenocarcinoma in mice, and co-expression of oncogenic Kras enhances tumor initiation. Additionally, individual Braf inactivating mutations are also oncogenic events. These findings suggest a potential therapeutic strategy for lung cancer patients with hypoactive BRAF.
Researchers at La Jolla Institute for Allergy and Immunology identify tissue-resident memory T cells as an important distinguishing factor between cancer patients whose immune system mounts an effective anti-tumor response. The study found that patients with a high density of these cells in tumor tissue survived significantly longer.
The new clinical guideline provides evidence-based recommendations on the use of stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer. For medically inoperable patients with high-risk clinical scenarios, SBRT is recommended as an alternative to surgery or salvage therapy.
Researchers have created detailed atlases of immune cells surrounding human tumors, revealing unique profiles that can estimate cancer prognosis and identify potential targets for early immunotherapy. The findings have the potential to inspire new precision immunotherapy clinical trials.
Researchers tracked lung tumour evolution in real-time to discover unstable chromosomes drive genetic diversity, increasing relapse risk. Circulating tumour DNA analysis reveals potential for personalised treatments to target resistant tumours.
Researchers discovered an antibody that normalizes tumor blood vessels, reducing volume and improving anti-cancer drug delivery. The antibody, ABTAA, restores vascular integrity in breast, lung, and brain tumors, leading to better oxygen supply and reduced metastasis.
Researchers have pinpointed a cause and potential treatment for inflammatory myofibroblastic tumors, a rare form of sarcoma that does not respond to radiation or chemotherapy. The drug ceritinib shows promise as a new treatment option.
Researchers at CSI Singapore found that inhibiting protein BMI1 can stop lung cancer growth. Low levels of C/EBPa protein result in poorer survival and high expression of BMI1.
A team of investigators identified a subtype of human adenocarcinoma that may be amenable to a new therapy. The research found that tumor suppressing C/EBPα works by restraining the expression of oncogenic protein BMI1, leading to an inverse correlation between the two molecules in NSCLC patients.
Researchers developed liquid biopsies to detect EGFR mutations in urine, plasma, and blood samples. The tests showed high sensitivity and specificity for identifying patients suitable for targeted treatment and predicting cancer recurrence.
Researchers identify unique immune cells that enhance anti-tumor T cell responses in early-stage lung cancer. These hybrid neutrophils may help stimulate natural protection against tumor development.
A study by Stanford University researchers has identified CD47, a protein highly expressed on the surface of small-cell lung cancer cells, as a potential therapeutic target. Blocking this protein with immunotherapies may stimulate the immune system to destroy cancer cells, offering new hope for treating this deadly disease.
Patients with EGFR expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy. The addition of necitumumab improves overall survival and progression-free survival by 21% and 16%, respectively, in patients whose tumours express the EGFR protein.
Researchers from Massachusetts General Hospital report that inducing cytotoxic T cell infiltration into lung tumors can make them sensitive to checkpoint blockade. Combining chemotherapy with immune checkpoint therapies achieves long-lasting control of tumor growth in animal models, expanding the potential for effective treatment.
Researchers at CNIO find potential therapy for aggressive type of lung cancer in preclinical models, combining dasatinib and demcizumab to reduce tumour size and improve survival rates. The study uses genetically modified mice and validates effectiveness with human samples, paving the way for clinical trials.
Scientists at CRI have discovered new complexities underlying cancer biology, overturning a nearly century-old perception about cancer metabolism. The study found that tumors use multiple nutrients for energy, and the surrounding environment influences metabolic activity.
Researchers suggest significant improvements in mesothelioma staging by incorporating tumor weight and volume into the current TNM system. This could lead to more accurate prognoses and personalized treatment plans for patients.
Researchers at UTA have developed a new, personalized respiratory-motion system that captures images of the lung when it is depressed, providing clearer and more precise images of tumors. This technology promises to lead to improved and more precise radiation therapy for lung cancer patients.
Scientists at the Salk Institute have discovered a molecule called EphA2 that stifles aggressive growth of common and deadly type of lung cancer in humans. The enzyme normally polices tissue growth but when mutated, cellular systems can run amok, leading to tumors.
PharmaMar has initiated a multicenter, international phase II Basket trial to evaluate the efficacy and safety of PM1183 (lurbinectedin) in patients with various advanced solid tumors. The trial will assess the overall response rate, duration of response, and pharmacokinetic properties of the drug.
The International Association for the Study of Lung Cancer has released new data for the TNM classification of lung cancer, which will inform the Eighth Edition of the staging manual. The new database includes 94,708 patients diagnosed worldwide from 1999-2010 and analyzes tumor size, lymph node involvement, and metastatic status.
A new study reports that a targeted molecular contrast agent can be used to cause lung adenocarcinomas to fluoresce during pulmonary surgery, enabling real-time optical imaging and precise visualization of tumor margins. The technique showed promise in localizing tumors and detecting metastatic cancer cells with high accuracy.
Researchers at the University of Louisville have detailed a crucial connection between silica exposure and rapid lung cancer progression, highlighting the role of inflammatory mediator LTB4 and its receptor BLT1. The study's findings suggest that novel treatment strategies for both silicosis and associated lung cancers may be possible.
Researchers have developed a model that allows for precise targeting of tumors while reducing dose to surrounding tissues. The rescanning technique compensates for tumor motion, averaging out the delivered dose while keeping doses to normal tissues low.